Cigna Group (NYSE:CI) Posts Quarterly Earnings Results, Beats Expectations By $0.18 EPS

Cigna Group (NYSE:CI) issued its quarterly earnings data on Thursday. The health services provider reported $7.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.60 by $0.18, Zacks reports. Cigna Group had a net margin of 2.26% and a return on equity of 19.75%. The business had revenue of $70.04 billion during the quarter, compared to the consensus estimate of $70.14 billion. During the same period in the prior year, the firm posted $7.20 EPS. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. Cigna Group updated its FY 2026 guidance to 30.450- EPS.

Here are the key takeaways from Cigna Group’s conference call:

• Second-quarter results exceeded expectations: revenue reached $71.7 billion and adjusted EPS was $7.78, prompting Cigna to raise its 2026 adjusted EPS outlook to at least $30.45.
• Evernorth Specialty and Care Services adjusted earnings grew 22% year over year to $1.1 billion, supported by specialty utilization, faster biosimilar and specialty-generic adoption, operating efficiencies, and contributions from Shields Health Solutions.
• Cigna Healthcare adjusted earnings rose 17%, with membership growth in the U.S. employer business and slightly favorable medical-cost experience; full-year segment earnings guidance increased to at least $4.55 billion.
• Evernorth Pharmacy Benefit Services earnings declined to $609 million due to large contract renewals and investments in the rebate-free Signature model, while moderating GLP-1 utilization and faster biosimilar adoption are expected to pressure the business through the rest of 2026.
• Management continues investing in AI-enabled programs such as Pharmacy Forward and enhanced care coordination, which it says could cut specialty therapy-start times in half, support 20% more customers with complex needs, and reduce avoidable inpatient stays.

Cigna Group Stock Down 1.6%

Cigna Group stock traded down $4.52 during trading hours on Friday, hitting $283.14. 796,114 shares of the stock traded hands, compared to its average volume of 1,674,018. Cigna Group has a one year low of $239.51 and a one year high of $315.47. The firm’s 50-day moving average price is $286.75 and its two-hundred day moving average price is $281.12. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.69. The company has a market cap of $74.90 billion, a PE ratio of 12.01, a PEG ratio of 1.14 and a beta of 0.29.

Cigna Group Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be issued a $1.56 dividend. The ex-dividend date is Tuesday, September 8th. This represents a $6.24 annualized dividend and a yield of 2.2%. Cigna Group’s dividend payout ratio (DPR) is 26.45%.

Analyst Ratings Changes

Several analysts have recently issued reports on CI shares. Deutsche Bank Aktiengesellschaft lowered shares of Cigna Group from a “buy” rating to a “hold” rating and lowered their price target for the company from $303.00 to $302.00 in a research report on Wednesday, May 20th. Wall Street Zen upgraded Cigna Group from a “hold” rating to a “buy” rating in a report on Saturday, June 20th. Wolfe Research reaffirmed an “outperform” rating and issued a $315.00 target price on shares of Cigna Group in a research note on Tuesday, June 16th. Jefferies Financial Group cut their price target on shares of Cigna Group from $333.00 to $330.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Finally, Piper Sandler dropped their target price on shares of Cigna Group from $370.00 to $346.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $341.60.

Insider Activity

In other news, CAO Jamie G. Kates sold 899 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $298.61, for a total value of $268,450.39. Following the sale, the chief accounting officer directly owned 2,368 shares of the company’s stock, valued at $707,108.48. The trade was a 27.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO David Cordani sold 201,878 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $292.82, for a total value of $59,113,915.96. Following the completion of the sale, the chief executive officer directly owned 34,337 shares in the company, valued at approximately $10,054,560.34. This represents a 85.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.60% of the company’s stock.

Hedge Funds Weigh In On Cigna Group

Hedge funds and other institutional investors have recently bought and sold shares of the stock. IHT Wealth Management LLC lifted its holdings in Cigna Group by 2.5% in the fourth quarter. IHT Wealth Management LLC now owns 1,535 shares of the health services provider’s stock valued at $423,000 after buying an additional 38 shares during the period. Lyell Wealth Management LP raised its holdings in Cigna Group by 4.5% in the fourth quarter. Lyell Wealth Management LP now owns 970 shares of the health services provider’s stock worth $267,000 after purchasing an additional 42 shares during the period. Compound Planning Inc. boosted its position in shares of Cigna Group by 2.7% during the fourth quarter. Compound Planning Inc. now owns 1,944 shares of the health services provider’s stock worth $535,000 after purchasing an additional 51 shares in the last quarter. Diversify Wealth Management LLC increased its position in shares of Cigna Group by 2.7% in the 2nd quarter. Diversify Wealth Management LLC now owns 2,065 shares of the health services provider’s stock valued at $683,000 after buying an additional 54 shares in the last quarter. Finally, Tocqueville Asset Management L.P. lifted its holdings in Cigna Group by 1.2% during the third quarter. Tocqueville Asset Management L.P. now owns 4,924 shares of the health services provider’s stock worth $1,419,000 after acquiring an additional 56 shares in the last quarter. Institutional investors own 86.99% of the company’s stock.

More Cigna Group News

Here are the key news stories impacting Cigna Group this week:

• Positive Sentiment: Cigna reported second-quarter adjusted earnings of $7.78 per share, exceeding analyst expectations, while total revenue increased 7% year over year to $71.7 billion. Growth in Cigna Healthcare and Evernorth’s pharmacy and specialty-drug businesses supported the results. Cigna second-quarter results
• Positive Sentiment: The company raised its 2026 adjusted earnings outlook to at least $30.45 per share, slightly above consensus, and is targeting approximately 10% earnings growth and mid-single-digit revenue growth through 2027. Reuters Cigna outlook
• Positive Sentiment: Analyst sentiment remains supportive: Barclays raised its price target from $304 to $310 while maintaining an Equal Weight rating. Cigna also has substantial financial flexibility, including $6.3 billion in cash, ongoing share repurchases and a $1.56-per-share dividend. Cigna valuation analysis
• Neutral Sentiment: At roughly 12 times earnings, Cigna remains viewed as deeply discounted relative to its earnings growth prospects. However, Barclays’ Equal Weight stance suggests the improved outlook may already be partly reflected in the valuation.
• Negative Sentiment: Management continues to face higher medical costs across the health-insurance industry. Cigna also expects slower growth in prescriptions for popular GLP-1 drugs, creating concern about the pace of future pharmacy-benefit growth. Cigna GLP-1 prescription outlook
• Negative Sentiment: Recent insider activity has been exclusively selling, including substantial sales by Chairman and CEO David Cordani. While such transactions may be routine, they can add to investor caution.

Cigna Group Company Profile

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.